Isaac Manke
Known title: DirectorCIK: 0001622769
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Q32 Bio to Present Late‑Breaking Results of Bempikibart Trial at EADV Congress. Q32 Bio will present late‑breaking results from Part B of its SIGNAL‑AA Phase 2a study of Bempikibart for alopecia areata at the European Academy of Dermatology and Venereology Congress. The company also shared additional 36‑week data from the same study earlier in the congress. These updates provide new information on the drug’s safety and efficacy profile, which may influence market perception of the company’s pipeline.
Transaction History
| ADXN | ▲ Buy | Grant | 219,561 | $0 | 9/2/2026 | View on chart |
| ADXN | ▼ Sell | Other | 219,561 | $0 | 9/2/2026 | View on chart |
| QTTB | ▲ Buy | Option Exercise | 53,521 | $150K | 6/30/2026 | View on chart |
| OKUR | ▲ Buy | Grant | 5,258 | $0 | 12/31/2025 | View on chart |
| OKUR | ▲ Buy | Grant | 5,545 | $0 | 9/30/2025 | View on chart |
| OKUR | ▲ Buy | Grant | 6,311 | $0 | 6/30/2025 | View on chart |
| OKUR | ▲ Buy | Grant | 3,469 | $0 | 3/31/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Addex Therapeutics Reports Q2 2026 Results and Management Changes
Addex Therapeutics announced executive management changes alongside its Q2 2026 earnings report. The company reported sales of $12,650, a decrease from $44,031 in the same period last year. Additionally, the company provided an update on its corporate status during the half-year results release.
Addex Therapeutics Reports Q2 2026 Results and Management Changes. Addex Therapeutics announced executive management changes alongside its Q2 2026 earnings report. The company reported sales of $12,650, a decrease from $44,031 in the same period last year. Additionally, the company provided an update on its corporate status during the half-year results release.